New Two-Step transplant shows promise against tough blood cancers
NCT ID NCT01315132
First seen Mar 21, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. The approach uses a drug called cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a serious side effect. The goal was to help more patients survive at least one year after the transplant. The study included 47 patients up to age 65.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.